Inspector AI vs Manual Claims Review
Manual pharmaceutical claims review cannot scale to the volume needed. Learn how automation with 25 detection rules achieves 100% coverage with consistency and speed that human review cannot match.
Manual Review: A Process That Does Not Scale
Manual pharmaceutical claims review has been the default control method for many health insurers. Auditors and analysts review transactions looking for irregularities: unusual amounts, suspicious frequencies, questionable drug combinations. It is meticulous work that requires pharmaceutical knowledge and experience in fraud patterns.
The fundamental problem is one of scale. An insurer with 50,000 members generates hundreds of thousands of pharmaceutical transactions per year. A manual review team — even a large one — can only review a sample. Typical audits cover between 1% and 5% of transactions. The other 95% to 99% passes without any review.
This is not a criticism of the reviewers' work — it is a structural limitation. Our analysis of Latin American health insurance claims revealed that 43.4% of pharmaceutical spend shows detectable anomalies. To find these anomalies manually, a reviewer would need to analyze the complete history of each patient over time, compare prescribing patterns across physicians, verify generic availability for every brand-name dispensation, and calculate cumulative doses per patient. This is physically impossible at scale.
Comparison: Coverage, Consistency, and Speed
The most important difference between manual review and Inspector AI is coverage. Manual review operates on samples — typically selected by high amounts or basic alerts. Inspector AI applies 25 specialized detection rules to 100% of transactions. There is no sampling, no selection — every dispensation is analyzed.
Consistency is the second critical difference. A human reviewer may identify a pattern one day and miss it the next. Fatigue, workload, and criteria differences between reviewers create variability. Inspector AI applies exactly the same criteria to every transaction, every time. If a rule detects early refills at a specific frequency, that rule is applied uniformly to all subscribers.
Speed is the third advantage. Manual review of a case can take hours or days. Inspector AI, through its FHIR PAS compatible API, can evaluate a transaction in real time — before the dispensation is approved. This transforms the model from post-payment detection to pre-dispensation prevention.
Finally, the cost per review is drastically different. The cost of an analyst reviewing transactions manually includes salary, training, supervision, and the opportunity cost of not investigating other cases. The marginal cost of analyzing one additional transaction with Inspector AI is virtually zero.
100%
Transaction coverage
25
Detection rules
43.4%
Spend with detectable anomalies
Where Manual Review Adds Value
Manual review should not be eliminated — it should be refocused. There are tasks where human judgment is superior to automated analysis. Clinical context evaluation is one of them. 80% of polypharmacy flags are correctly exempted by clinical logic — oncology, HIV, cardio-metabolic conditions, and neurology. An experienced reviewer understands when an apparently anomalous pattern has clinical justification.
Validation of automated findings is another crucial role. When Inspector AI identifies that 1 in 6 subscribers received a drug with no diagnostic justification, a human reviewer can verify whether an unrecorded diagnosis or coding error exists. Investigation of complex intentional fraud cases — where multiple actors coordinate to defraud — requires investigative skills that go beyond data analysis.
Communication with prescribers, pharmacies, and members about findings also requires the human touch. Explaining why a dispensation was questioned and negotiating changes in prescribing patterns are interpersonal skills, not analytical ones.
Integration: Automation as First Line, Human Review as Second
The optimal model uses automation as the first line of detection and human review as the second line of validation and investigation. Inspector AI analyzes 100% of transactions and classifies anomalies into categories: waste and utilization (20.3% of anomalous spend), generic substitution (10.8%), clinical mismatch (7.3%), behavioral fraud risk (4.6%), and financial anomalies (0.4%).
Human reviewers receive cases already categorized, prioritized by financial impact, and enriched with context. Instead of searching for problems in raw data, they validate specific findings. This multiplies productivity: a reviewer who previously could analyze 20 cases per day can now validate 50 or more pre-analyzed cases.
On the ~50,000-subscriber book we analyzed, the total financial impact observed was $5.1 million in one year. Generic substitution alone — with 71% of brand-name products having a generic available and less than 5% dispensed as generic — represented $4.53 million of that total. These findings would be virtually impossible to identify systematically through manual review.
Inspector AI offers a proof of concept in 3 weeks with no system integration required. Upload a sample of claims data and receive a detailed anomaly report that quantifies exactly what automated detection is finding that manual review cannot cover.
$5.1M
Annual impact observed on our 50K book
$4.53M/yr
Generic substitution
3 weeks
Proof of concept
Automate Your Pharmaceutical Claims Review
Discover what anomalies are escaping manual review. Free analysis of your data in 3 weeks, no system integration required.
Request Free Analysis